Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

Inclusion Criteria:

1. Participants legally competent to sign and give informed consent and, ifappropriate, assent as required by local laws.

2. Males and females, ages 6 years and older at time of signing Informed Consent (Screening). Only subjects 18 years and older will be enrolled at sites located inthe province of Québec in Canada.

3. Diagnosed with atopic dermatitis 6 months duration (3 months for children), asdetermined by the Investigator. Stable disease for the past 4 weeks with nosignificant flares in atopic dermatitis before screening.

4. Females of childbearing potential (FOCBP) must have a negative serum pregnancy testat Screening and a negative urine pregnancy test at Baseline/Day 1. In addition,sexually active FOCBP must agree to use at least one form of a highly effective orbarrier method of contraception throughout the trial.

5. In good health as judged by the Investigator.

6. Subjects considered reliable and capable of adhering to the Protocol and visitschedule, according to the judgment of the Investigator.

Exclusion Criteria:

1. Subjects with any serious medical condition or clinically significant abnormalitythat would prevent study participation or place the subject at significant risk, asjudged by the Investigator

2. Has unstable AD or any consistent requirement for high potency topical steroids.

3. Subjects who are unwilling to refrain from prolonged sun exposure and from using atanning bed or other artificial light emitting devices (LEDs) for 4 weeks prior toBaseline/Day 1 and during the study.

4. Females who are pregnant, wishing to become pregnant during the study, or arebreast-feeding.

5. Previous treatment with ARQ-151.

6. Subjects with a history of chronic alcohol or drug abuse within 6 months prior toScreening.

7. Parent(s)/legal guardian(s) who are unable to communicate, read, or understand thelocal language(s). Subjects who are unable to communicate, read or understand thelocal language, or who display another condition, which in the Investigator'sopinion, makes them unsuitable for clinical study participation.

8. Subjects who are family members of the clinical study site, clinical study staff, orsponsor, or family members of enrolled subjects living in the same house.